Evidence map›Paper›PMID 22083974›Full record

ArticleStem cells (Dayton, Ohio)2012

In vivo fate mapping identifies mesenchymal progenitor cells.

Danka Grcevic, Slavica Pejda, Brya G Matthews, Dario Repic, Liping Wang, Haitao Li, Mark S Kronenberg, Xi Jiang, Peter Maye, Douglas J Adams and 3 more

Open access · greenAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 252 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Danka GrcevicDepartment of Physiology and Immunology, School of Medicine, University of Zagreb, Zagreb Croatia.
Slavica Pejda
Brya G Matthews
Dario Repic
Liping Wang
Haitao Li
Mark S Kronenberg
Xi Jiang
Peter Maye
Douglas J Adams
David W Rowe
Hector L Aguila
Ivo Kalajzic
UConn Health · USUniversity of Zagreb · HR

Funding

Notch Signaling and Bone Fracture HealingR01AR055607 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Kurt David Hankenson, IVO Kalajzic · 2011 to 2026
$6.3M
TRANSGENES AS TOOLS TO ASSESS OSTEOBLAST LINEAGER01AR043457 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W. · 1995 to 2009
$2.8M
Osteoclasts from pluripotent stem cells as vectors to modify bone marrow environmRC1HL100569 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI AGUILA, HECTOR LEONARDO · 2010 to 2010
$792k
Evaluation of Osteocyte Dedifferentiation ProcessR21AR059315 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KALAJZIC, IVO · 2010 to 2011
$371k
NHLBI NIH HHS 1RC1HL100569-01NHLBI NIH HHS RC1 HL100569NIAMS NIH HHS AR043457NIAMS NIH HHS AR055607-01NIAMS NIH HHS AR059315-01NIAMS NIH HHS R01 AR043457NIAMS NIH HHS R01 AR055607NIAMS NIH HHS R21 AR059315
6 · The paper itself

Abstract

Adult mesenchymal progenitor cells have enormous potential for use in regenerative medicine. However, the true identity of the progenitors in vivo and their progeny has not been precisely defined. We hypothesize that cells expressing a smooth muscle α-actin promoter (αSMA)-directed Cre transgene represent mesenchymal progenitors of adult bone tissue. By combining complementary colors in combination with transgenes activating at mature stages of the lineage, we characterized the phenotype and confirmed the ability of isolated αSMA(+) cells to progress from a progenitor to fully mature state. In vivo lineage tracing experiments using a new bone formation model confirmed the osteogenic phenotype of αSMA(+) cells. In vitro analysis of the in vivo-labeled SMA9(+) cells supported their differentiation potential into mesenchymal lineages. Using a fracture-healing model, αSMA9(+) cells served as a pool of fibrocartilage and skeletal progenitors. Confirmation of the transition of αSMA9(+) progenitor cells to mature osteoblasts during fracture healing was assessed by activation of bone-specific Col2.3emd transgene. Our findings provide a novel in vivo identification of defined population of mesenchymal progenitor cells with active role in bone remodeling and regeneration.

Indexed as

Cell LineageActinsAnimalsAntigens, DifferentiationBone Marrow CellsBone RegenerationBone RemodelingCell DifferentiationFemaleFracture HealingGene Expression RegulationGreen Fluorescent ProteinsMaleMesenchymal Stem CellsMiceMice, TransgenicActinsAntigens, DifferentiationGreen Fluorescent ProteinsRecombinant Fusion Proteins

Identifiers

PMID22083974
PMCPMC3560295
OpenAlexW2115516793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.